References
- Austin M PV, Souza F GM, Goodwin G M. Lithium augmentation in antidepressant resistant patients. A quantitative analysis. Br J Psychiatry 1991; 159: 510–4
- Joffe R T, Singer W, Levitt A J, MacDonald C. A placebocontrolled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressant in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387–93
- Stein G, Bemadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634–40
- Katona C L, Abou-Saleh M, Harrison D A, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–86
- McCance-Katz E, Price L H, Chamey D S, Heninger G R. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 1992; 108: 93–97
- Committee on Safety of Medicines (1989). Fluvoxamine and fluoxetine—interaction with monoamine oxidase inhibitors, lithium and tryptophan. Current Problems, 26
- Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13
- Radomski J W, Dursun S M, Reveley M A. Toxic Serotonin Syndrome (TSS): An update and revised diagnosis criteria. J Psychopharmacology 1995; 1(suppl)A21, (84).
- Bauer M. The combined use of lithium and SSRIs. J Serotonin Res 1995; 2: 69–76
- Taylor D P, Eison M S, Riblet L A, et al. Selective 5HT receptor blockade: pharmacologic studies of BMY13754, a non tricyclic antidepressant candidate. Soc Neurosci Abstr 1982; 8: 465
- Sharpley A L, Walsh A ES, Cowen P J. Effect of nefazodone and lithium on sleep architecture in healthy men. J Psychopharmacol 1996; 10(suppl 1)26–29
- Montgomery S A, åsberg M A. A New Depression Scale Designed to be Sensitive to Change. Br J Psychiatry 1979; 134: 382–9
- Guy W. Early Clinical Drug Evaluation (ECDEU). Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD. 1976
- Hawley C J, Roberts A G, Walker M H. Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions. J Psychopharmacol 1994; 8: 266–7
- Hawley C J, Roberts A G, Baldwin D S. Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions. Int Clin Psychopharmacol 1994; 9: 31–33
- Dinan T G. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. 1. Austin MPV, Souza FGM, Goodwin GM (1991) Lithium augmentation in antidepressant resistant patients. A quantitative analysis. Br J Psychiatry 1993; 159: 510–4
- Joffe R T, Singer W, Levitt A J, MacDonald C. A placebocontrolled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressant in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387–93
- Stein G, Bemadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634–40
- Katona C L, Abou-Saleh M, Harrison D A, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry Scand 1995; 88: 300–1
- Hawley C J, Ratnam S, Pattinson H A, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: a preliminary study of 19 patients. J Psychopharmacol 1996; 10: 241–5